Protagonist Therapeutics Inc Ranked High in Biotechnology Field Despite Recent 0.72% Dip in Stock Price
April 28, 2023
Trending News 🌥️
Protagonist Therapeutics ($NASDAQ:PTGX) Inc is an American biopharmaceutical company focused on discovering, developing, and commercializing peptide-based drugs to treat diseases. The company’s mission is to develop small molecules and peptides to target biological pathways with disease-modifying potential. This week, the company’s stock price has dropped 0.72%, yet their standing in the biotechnology field remains high. According to InvestorsObserver, Protagonist Therapeutics Inc remains near the top of its industry group, receiving an overall rating of 80. Protagonist Therapeutics Inc has made significant strides in research and development efforts this past year, obtaining a number of patents in therapeutic areas such as oncology, fibrosis, and inflammatory diseases.
Protagonist’s commitment to its research and development efforts has earned it recognition and respect in the biotechnology field, which has likely contributed to the company’s current rank despite its 0.72% dip in stock price this week. In summary, Protagonist Therapeutics Inc remains near the top of its industry group despite its 0.72% dip in stock price this week. This is due in part to the company’s commitment to research and development efforts in therapeutic areas such as oncology, fibrosis, and inflammatory diseases. This could potentially increase its stock price and affirm its standing as one of the top biotechnology companies in the world.
Market Price
Protagonist Therapeutics Inc, a biotechnology company, had a rough day on the stock market on Thursday. The stock opened at $23.3 and closed at $22.7, resulting in a 2.5% dip from its prior closing price of $23.3. The company has been praised for its innovative approach to developing new treatments for various diseases and for its commitment to helping people with various medical conditions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 26.58 | -127.39 | -479.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -108.14 | 91.47 | 18.84 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 247.93 | 32.32 | 4.37 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 386.4% | – | -479.3% |
| FCF Margin | ROE | ROA |
| -409.8% | -34.7% | -32.1% |
Analysis
GoodWhale has conducted an analysis of PROTAGONIST THERAPEUTICS‘s wellbeing. We used our star chart to assess the health of the company, assigning them a score of 5/10. This score reflects the company’s current cashflows and debt, as well as their potential to pay off debt and fund future operations. Our analysis also revealed that PROTAGONIST THERAPEUTICS is strong in asset and growth, but weak in dividend and profitability. Based on these results, we have classified the company as a ‘rhino’ – a type of company that has achieved moderate revenue or earnings growth. Investors who are interested in this type of company may be attracted to PROTAGONIST THERAPEUTICS for its moderate growth potential. They may also be interested in the company’s strong assets, which can be used as collateral for future investments or lending. Additionally, investors may be reassured by the company’s ability to pay off debt and fund future operations. More…
Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Protagonist Therapeutics Inc. is a biotechnology company engaged in the discovery and development of peptide-based drugs. This week, the stock has fallen by 0.72%, but it still holds an overall rating of 80 by InvestorsObserver, placing it near the top of its industry group. In conclusion, Protagonist Therapeutics Inc. is an attractive investment option for investors seeking exposure to the biotechnology sector.
